ReviewJournal of neuro-oncology2024
The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.
Review in Journal of neuro-oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 18 citations in OpenAlex.
- GammaTileCancers · 2026Article
- Cesium-131 brachytherapy for central nervous system salvage therapy.Journal of neuro-oncology · 2026Article
- Local control and leptomeningeal disease after resection and GammaTile brachytherapy for newly diagnosed brain metastases: results from a prospective registry.Journal of neuro-oncology · 2026Observational
- Redefining the therapeutic landscape of glioblastomas and brain metastasis through cesium brachytherapy and low-kV intra-operative radiation therapy (IORT).Journal of neuro-oncology · 2025Review
- Cesium-131 collagen tile brachytherapy for salvage of recurrent intracranial metastases.Journal of neuro-oncology · 2025Article
- Emerging Technologies in Radiation Therapy: Replacing Traditional Isotope-based Modalities.Health physics · 2025Review
- Interstitial High-Dose-Rate Brachytherapy for Radiorecurrent Atypical Meningioma: A Brief Report.Advances in radiation oncology · 2025Article
- Glioblastoma: From Pathophysiology to Novel Therapeutic Approaches.Biomedicines · 2025Review
- Targeting the glioblastoma resection margin with locoregional nanotechnologies.Nature reviews. Clinical oncology · 2025Review
- Article
- Meningioma: Novel Diagnostic and Therapeutic Approaches.Biomedicines · 2025Review
- The research progress on meningeal metastasis in solid tumors.Discover oncology · 2025Review
- Recent technology development in radiotherapy for intracranial meningiomas.Frontiers in neurology · 2025Review
- Early experience and perioperative risk of GammaTile for upfront brain metastases: Report from a prospective multicenter study.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant and benign brain tumors with a propensity to recur continue to be a clinical challenge despite decades-long efforts to develop systemic and more advanced local therapies. GammaTile (GT Medical Technologies Inc., Tempe AZ) has emerged as a novel brain brachytherapy device placed during surgery, which starts adjuvant radiotherapy immediately after resection. GammaTile received FDA clearance in 2018 for any recurrent brain tumor and expanded clearance in 2020 to include upfront use in any malignant brain tumor. More than 1,000 patients have been treated with GammaTile to date, and several publications have described technical aspects of the device, workflow, and clinical outcome data. Herein, we review the technical aspects of this brachytherapy treatment, including practical physics principles, discuss the available literature with an emphasis on clinical outcome data in the setting of brain metastases, glioblastoma, and meningioma, and provide an overview of the open and pending clinical trials that are further defining the efficacy and safety of GammaTile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.